Whyte Michael P, Singhellakis Panagiotis N, Petersen Michael B, Davies Michael, Totty William G, Mumm Steven
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St Louis, Missouri 63131, USA.
J Bone Miner Res. 2007 Jun;22(6):938-46. doi: 10.1359/jbmr.070307.
The oldest person (60 yr) with juvenile Paget's disease is homozygous for the TNFRSF11B mutation 966_969delTGACinsCTT. Elevated circulating levels of immunoreactive OPG and soluble RANKL accompany this genetic defect that truncates the OPG monomer, preventing formation of OPG homodimers.
Juvenile Paget's disease (JPD), a rare autosomal recessive disorder, features skeletal pain, fracture, and deformity from extremely rapid bone turnover. Deafness and sometimes retinopathy also occur. Most patients have diminished osteoprotegerin (OPG) inhibition of osteoclastogenesis caused by homozygous loss-of-function defects in TNFRSF11B, the gene that encodes OPG. Circulating immunoreactive OPG (iOPG) is undetectable with complete deletion of TNFRSF11B but normal with a 3-bp in-frame deletion.
We summarize the clinical course of a 60-yr-old Greek man who is the second reported, oldest JPD patient, including his response to two decades of bisphosphonate therapy. Mutation analysis involved sequencing all exons and adjacent mRNA splice sites of TNFRSF11B. Over the past 4 yr, we used ELISAs to quantitate his serum iOPG and soluble RANKL (sRANKL) levels.
Our patient suffered progressive deafness and became legally blind, although elevated markers of bone turnover have been normal for 6 yr. He carries the same homozygous mutation in TNFRSF11B (966_969delTGACinsCTT) reported in a seemingly unrelated Greek boy and Croatian man who also have relatively mild JPD. This frame-shift deletes 79 carboxyterminal amino acids from the OPG monomer, including a cysteine residue necessary for homodimerization. Nevertheless, serum iOPG and sRANKL levels are persistently elevated.
Homozygosity for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT) causes JPD in the second reported, oldest patient. Elevated circulating iOPG and sRANKL levels complement evidence that this deletion/insertion omits a cysteine residue at the carboxyterminus needed for OPG homodimerization.
患有青少年佩吉特病的最年长者(60岁)为TNFRSF11B突变966_969delTGACinsCTT的纯合子。这种基因缺陷会截断骨保护素(OPG)单体,阻止OPG同源二聚体的形成,同时伴有循环中免疫反应性OPG和可溶性核因子κB受体活化因子配体(sRANKL)水平升高。
青少年佩吉特病(JPD)是一种罕见的常染色体隐性疾病,其特征是由于骨转换极快导致骨骼疼痛、骨折和畸形。还会出现耳聋,有时也会出现视网膜病变。大多数患者因编码OPG的基因TNFRSF11B的纯合功能丧失缺陷,导致骨保护素(OPG)对破骨细胞生成的抑制作用减弱。完全缺失TNFRSF11B时无法检测到循环免疫反应性OPG(iOPG),但存在3个碱基的框内缺失时则正常。
我们总结了一名60岁希腊男性的临床病程,他是第二例有报道的、年龄最大的JPD患者,包括他对二十年双膦酸盐治疗的反应。突变分析包括对TNFRSF11B的所有外显子和相邻mRNA剪接位点进行测序。在过去4年中,我们使用酶联免疫吸附测定法(ELISA)定量他的血清iOPG和sRANKL水平。
我们的患者出现进行性耳聋并失明,但骨转换升高标志物在6年中一直正常。他携带与一名看似无关的希腊男孩和一名克罗地亚男性中报道的相同的TNFRSF11B纯合突变(966_969delTGACinsCTT),他们也患有相对轻度的JPD。这种移码突变从OPG单体中删除了79个羧基末端氨基酸,包括同源二聚化所需的一个半胱氨酸残基。然而,血清iOPG和sRANKL水平持续升高。
TNFRSF11B“巴尔干”突变(966_969delTGACinsCTT)的纯合性在第二例有报道的、年龄最大的患者中导致JPD。循环中iOPG和sRANKL水平升高补充了证据,表明这种缺失/插入遗漏了OPG同源二聚化所需的羧基末端的一个半胱氨酸残基。